

UBS AG
Form 424B2
December 27, 2018

The information in this Preliminary Terms Supplement is not complete and may be changed. We may not sell these Securities until the Final Terms Supplement, the Prospectus Supplement, the accompanying Product Supplement and the Prospectus (collectively, the "Offering Documents") are delivered in final form. The Offering Documents are not an offer to sell these Securities, and we are not soliciting offers to buy these Securities in any state where the offer or sale is not permitted.

Subject to Completion
Dated December 27, 2018

PRELIMINARY TERMS
SUPPLEMENT

Filed Pursuant to Rule 424(b)(2)

Registration Statement No.
333-225551

Preliminary Terms Supplement

UBS AG Trigger Phoenix Autocallable Optimization Securities

UBS AG \$ Securities Linked to the shares of The Financial Select Sector SPDR® Fund due on or about December 31, 2020

Indicative Terms

Issuer	UBS AG, London Branch
Principal Amount	\$10.00 per security. The Securities are offered at a minimum investment of 100 Securities at \$10.00 per Security (representing a \$1,000 investment) and integral multiples of \$10.00 in excess thereof.
Term	Approximately 24 months, unless called earlier.
Underlying Asset	The shares of The Financial Select Sector SPDR® Fund
Contingent Coupon	If the closing price of the underlying asset is equal to or greater than the coupon barrier on any observation date, UBS will pay you the contingent coupon applicable to such observation date.

If the closing price of the underlying asset is less than the coupon barrier on any observation date, the contingent coupon applicable to such observation date will not be payable and UBS will not make any payment to you on the relevant coupon payment date.

The contingent coupon will be a fixed amount based upon equal quarterly installments at the per annum contingent coupon rate. Contingent coupons are not guaranteed and UBS will not pay you the contingent coupon for any observation date on which the closing price of the underlying asset is less than the coupon barrier. The table below sets forth each observation date and a hypothetical contingent coupon for the Securities. The table below assumes a

Edgar Filing: UBS AG - Form 424B2

contingent coupon rate of 8.23% per annum. The actual contingent coupon rate will be set at the time the trade is placed on the trade date. Amounts in the table below may have been rounded for ease of analysis.

Observation Date*	Contingent Coupon (per security)
27-Mar-2019	\$0.2058
27-Jun-2019	\$0.2058
27-Sep-2019	\$0.2058
27-Dec-2019	\$0.2058
27-Mar-2020	\$0.2058
29-Jun-2020	\$0.2058
28-Sep-2020	\$0.2058
28-Dec-2020	\$0.2058

*Observation dates are subject to the market disruption event provisions set forth in the accompanying product supplement.

Contingent Coupon Rate 8.23% to 8.78% per annum (or approximately 2.058% to 2.195% per outstanding quarter). The actual contingent coupon rate will be set at the time the trade is placed on the trade date.

Automatic Call Feature The Securities will be called automatically if the closing price of the underlying asset on any observation date is equal to or greater than the initial price. If the Securities are called on any observation date, UBS will pay you on the corresponding coupon payment date a cash payment per Security equal to your principal amount plus the contingent coupon otherwise due on such date pursuant to the contingent coupon feature. No further amounts will be owed to you under the Securities.

If the Securities are not called and the final price is equal to or greater than the trigger price and coupon barrier, UBS will pay you a cash payment per Security on the maturity date equal to your principal plus the contingent coupon otherwise due on the maturity date.

Payment at Maturity (per Security) If the Securities are not called and the final price is less than the trigger price, UBS will pay you a cash payment on the maturity date of significantly less than the principal amount, if anything, resulting in a loss of principal that is proportionate to the decline of the underlying asset, for an amount equal to $\$10 + (\$10 \times \text{underlying return})$.

$$\frac{\text{Final Price} - \text{Initial Price}}{\text{Initial Price}}$$

Underlying Return

$$\frac{\text{Final Price} - \text{Initial Price}}{\text{Initial Price}}$$

Closing Price	On any trading day, the last reported sale price (or, in the case of NASDAQ, the official closing price) of the underlying asset during the principal trading session on the principal national securities exchange on which it is listed for trading, as determined by the calculation agent.
Initial Price	The closing price of the underlying asset on the trade date, as determined by the calculation agent and as may be adjusted in the case of certain corporate events, as described in the accompanying product supplement.
Trigger Price/Coupon Barrier	Both 80.00% of the initial price of the underlying asset, as determined by the calculation agent and as may be adjusted in the case of certain corporate events, as described in the accompanying product supplement.
Final Price	The closing price of the underlying asset on the final valuation date, as determined by the calculation agent and subject to adjustments in the case of certain corporate events, as described in the accompanying product supplement.
Trade Date	December 27, 2018
Settlement Date	December 31, 2018
Final Valuation Date	December 28, 2020. The final valuation date may be subject to postponement in the event of a market disruption event, as described in the accompanying product supplement.
Maturity Date	December 31, 2020. The maturity date may be subject to postponement in the event of a market disruption event, as described in the accompanying product supplement.
Coupon Payment Dates	Three business days following each observation date, except the coupon payment date for the final valuation date will be the maturity date.
CUSIP	[]
ISIN	[]
Valoren	[]

The estimated initial value based on an issuance size of approximately \$100,000 of the Securities as of the trade date is expected to be between 94.01% and 96.51% of the issue price to the public for Securities linked to the underlying asset. The range of the estimated initial value of the Securities was determined on the date of this preliminary terms supplement by reference to UBS' internal pricing models, inclusive of the internal funding rate. For more information about secondary market offers and the estimated initial value of the Securities, see "Key Risks - Fair value considerations" and "Key Risks - Limited or no secondary market and secondary market price considerations" in this preliminary terms supplement.

Notice to investors: the Securities are significantly riskier than conventional debt instruments. The issuer is not necessarily obligated to repay the full principal amount of the Securities at maturity, and the Securities may have the same downside market risk as the underlying asset. This market risk is in addition to the credit risk inherent in purchasing a debt obligation of UBS. You should not purchase the Securities if you do not understand or are not comfortable with the significant risks involved in investing in the Securities.

You should carefully consider the risks described under "Key Risks" in this preliminary terms supplement, under "Key Risks" beginning on page 3 of the prospectus supplement and under "Risk Factors" beginning on page PS-9 of the accompanying product supplement before purchasing any Securities. Events relating to any of those risks, or other risks and uncertainties, could adversely affect the market value of, and the return on, your Securities. You may lose a significant portion or all of your initial investment in the Securities. The Securities will not be listed or displayed on any securities exchange or any electronic communications network.

Neither the Securities and Exchange Commission nor any other regulatory body has approved or disapproved of these Securities or passed upon the adequacy or accuracy of this preliminary terms supplement, the previously delivered prospectus supplement, the accompanying product supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.

The Securities are not bank deposits and are not insured by the Federal Deposit Insurance Corporation or any other governmental agency.

See "Additional Information about UBS and the Securities" in this preliminary terms supplement. The Securities we are offering will have the terms set forth in the Prospectus Supplement dated November 1, 2018 relating to the Securities, the accompanying product supplement, the accompanying prospectus and this preliminary terms supplement.

Offering of Securities	Issue Price to Public		Underwriting Discount		Proceeds to UBS AG	
	Total	Per Security	Total	Per Security	Total	Per Security
Securities linked to the shares of The Financial Select Sector SPDR® Fund	\$	100%	\$	1.50%	\$	98.50%

UBS Financial Services Inc.

UBS Investment Bank

Additional Information About UBS and the Securities

UBS has filed a registration statement (including a prospectus, as supplemented by a product supplement and a prospectus supplement for the Securities) with the Securities and Exchange Commission, or SEC, for the offering for which this preliminary terms supplement relates. Before you invest, you should read these documents and any other documents relating to the Securities that UBS has filed with the SEC for more complete information about UBS and this offering. You may obtain these documents for free from the SEC website at www.sec.gov. Our Central Index Key, or CIK, on the SEC website is 0001114446.

You may access these documents on the SEC website at www.sec.gov as follows:

- Prospectus supplement dated November 1, 2018:
<http://www.sec.gov/Archives/edgar/data/1114446/000091412118002132/ub46175276-424b2.htm>
- Market-Linked Securities product supplement dated October 31, 2018:
<http://www.sec.gov/Archives/edgar/data/1114446/000091412118002085/ub47016353-424b2.htm>
- Prospectus dated October 31, 2018:
<http://www.sec.gov/Archives/edgar/data/1114446/000119312518314003/d612032d424b3.htm>

References to "UBS," "we," "our" and "us" refer only to UBS AG and not to its consolidated subsidiaries. In this document, "Trigger Phoenix Autocallable Optimization Securities" or the "Securities" refer to the Securities that are offered hereby. Also, references to the "prospectus supplement" mean the UBS prospectus supplement, dated November 1, 2018, references to "Market-Linked Securities product supplement" mean the UBS product supplement, dated October 31, 2018, relating to the Securities generally, and references to the "accompanying prospectus" mean the UBS prospectus titled "Debt Securities and Warrants", dated October 31, 2018.

This preliminary terms supplement, together with the documents listed above, contains the terms of the Securities and supersedes all other prior or contemporaneous oral statements as well as any other written materials including preliminary or indicative pricing terms, correspondence, trade ideas, structures for implementation, sample structures, brochures or other educational materials of ours. You should carefully consider, among other things, the matters set forth in “Key Risks” and in “Risk Factors” in the accompanying product supplement, as the Securities involve risks not associated with conventional debt securities. We urge you to consult your investment, legal, tax, accounting and other advisors before deciding to invest in the Securities

UBS reserves the right to change the terms of, or reject any offer to purchase, the Securities prior to their issuance. In the event of any changes to the terms of the Securities, UBS will notify you and you will be asked to accept such changes in connection with your purchase. You may also choose to reject such changes in which case UBS may reject your offer to purchase.

Key Risks

An investment in the Securities involves significant risks. Some of the risks that apply to the Securities are summarized here and are comparable to the corresponding risks discussed in the "Key Risks" section of the prospectus supplement, but we urge you to read the more detailed explanation of risks relating to the Securities generally in “Risk Factors” section of the accompanying product supplement. We also urge you to consult your investment, legal, tax, accounting and other advisors before you invest in the Securities.

- **Risk of loss at maturity** - The Securities differ from ordinary debt securities in that UBS will not necessarily pay the full principal amount of the Securities at maturity. If the Securities are not called, UBS will repay you the principal amount of your Securities in cash only if the final price of the underlying asset is equal to or greater than the trigger price and will only make such payment at maturity. If the Securities are not called and the final price is less than the trigger price, you will be fully exposed to the negative underlying return and lose a significant portion or all of your initial investment in an amount proportionate to the decline in the price of the underlying asset.
- **The contingent repayment of your principal applies only at maturity** - You should be willing to hold your Securities to maturity. If you are able to sell your Securities prior to maturity in the secondary market, you may have to sell them at a loss relative to your initial investment even if the then-current underlying asset price is equal to or greater than the trigger price at that time.
- **You may not receive any contingent coupons** - UBS will not necessarily pay periodic contingent coupons on the Securities. If the closing price of the underlying asset on an observation date is less than the coupon barrier, UBS will not pay you the contingent coupon applicable to such observation date. If the closing price of the underlying asset is less than the coupon barrier on each of the observation dates, UBS will not pay you any contingent coupons during the term of, and you will not receive a positive return on, your Securities. Generally, this non-payment of the contingent coupon coincides with a period of greater

risk of principal loss on your Securities.

Your potential return on the Securities is limited and you will not participate in any appreciation of the underlying asset - The return potential of the Securities is limited to the contingent coupon rate, regardless of the appreciation of the underlying asset. In addition, the total return on the Securities will vary based on the number of observation dates on which the requirements of the contingent coupon have been met prior to maturity or an automatic call. Further, if the Securities are called due to the automatic call feature, you will not receive any contingent coupons or any other payment in respect of any observation dates after the applicable call settlement date. Since the Securities could be called as early as the first observation date, the total return on the Securities could be minimal. If the Securities are not called, you will not participate in any appreciation in the price of the underlying asset even though you will be subject to the underlying asset's risk of decline. As a result, the return on an investment in the Securities could be less than the return on a direct investment in the underlying asset.

Higher contingent coupon rates are generally associated with a greater risk of loss - Greater expected volatility with respect to the underlying asset reflects a higher expectation as of the trade date that the price of such underlying asset could close below its trigger price on the final valuation date of the Securities. This greater expected risk will generally be reflected in a higher contingent coupon rate for that Security. However, an underlying asset's volatility can change significantly over the term of the Securities and the price of the underlying asset for your Securities could fall sharply, which could result in a significant loss of principal.

Reinvestment risk - The Securities will be called automatically if the closing price of the underlying asset is equal to or greater than the initial price on any observation date. In the event that the Securities are called prior to maturity, there is no guarantee that you will be able to reinvest the proceeds from an investment in the Securities at a comparable rate of return for a similar level of risk. To the extent you are able to reinvest such proceeds in an investment comparable to the Securities, you will incur transaction costs and the original issue price for such an investment is likely to include certain built-in costs such as dealer discounts and hedging costs.

Greater expected volatility generally indicates an increased risk of loss at maturity - "Volatility" refers to the frequency and magnitude of changes in the price of the underlying asset. The greater the expected volatility of the underlying asset as of the trade date, the greater the expectation is as of the trade date that the closing price of the underlying asset could be less than the coupon barrier on any observation date and that the final price of the underlying asset could be less than the trigger price on the final valuation date and, as a consequence, indicates an increased risk of loss. However, the underlying asset's volatility can change significantly over the term of the Securities, and a relatively lower coupon barrier and/or trigger price may not necessarily indicate that the Securities have a greater likelihood of a return of principal at maturity. You should be willing to accept the downside market risk of the underlying asset and the potential to lose a significant portion or all of your initial investment.

Credit risk of UBS - The Securities are unsubordinated, unsecured debt obligations of the issuer, UBS, and are not, either directly or indirectly, an obligation of any third party. Any payment to be made on the Securities,

including any repayment of principal, depends on the ability of UBS to satisfy its obligations as they come due. As a result, the actual and perceived creditworthiness of UBS may affect the market value of the Securities and, in the event UBS were to default on its obligations, you may not receive any amounts owed to you under the terms of the Securities and you could lose your entire investment.

Market risk - The price of the underlying asset can rise or fall sharply due to factors specific to that underlying asset and (i) in the case of common stock or American depositary receipts, its issuer (the "underlying asset issuer") or (ii) in the case of an exchange traded fund, the securities, futures contracts or physical commodities constituting the assets of that underlying asset. These factors include price volatility, earnings, financial conditions, corporate, industry and regulatory developments, management changes and decisions and other events, as well as general market factors, such as general market volatility and levels, interest rates and economic and political conditions. You, as an investor in the Securities, should make your own investigation into the underlying asset issuer and the underlying asset for your Securities. **We urge you to review financial and other information filed periodically by the underlying asset issuer with the SEC.**

- **Fair value considerations.**

The issue price you pay for the Securities will exceed their estimated initial value - The issue price you pay for the Securities will exceed their estimated initial value as of the trade date due to the inclusion in the issue price of the underwriting discount, hedging costs, issuance costs and projected profits. As of the close of the relevant markets on the trade date, we will determine the estimated initial value of the Securities by reference to our internal pricing models and it will be set forth in the final terms supplement. The pricing models used to determine the estimated initial value of the Securities incorporate certain variables, including the price, volatility and expected dividends on the underlying asset, prevailing interest rates, the term of the Securities and our internal funding rate. Our internal funding rate is typically lower than the rate we would pay to issue conventional fixed or floating rate debt securities of a similar term. The underwriting discount, hedging costs, issuance costs, projected profits and the difference in rates will reduce the economic value of the Securities to you. Due to these factors, the estimated initial value of the Securities as of the trade date will be less than the issue price you pay for the Securities.

The estimated initial value is a theoretical price; the actual price that you may be able to sell your Securities in any secondary market (if any) at any time after the trade date may differ from the estimated initial value - The value of your Securities at any time will vary based on many factors, including the factors described above and in "- Market risk" above and is impossible to predict. Furthermore, the pricing models that we use are proprietary and rely in part on certain assumptions about future events, which may prove to be incorrect. As a result, after the trade date, if you attempt to sell the Securities in the secondary market, the actual value you would receive may differ, perhaps materially, from the estimated initial value of the Securities determined by reference to our internal pricing models. The estimated initial value of the Securities does not represent a minimum or maximum price at which we or any of our affiliates would be willing to purchase your Securities in any secondary market at any time.

Our actual profits may be greater or less than the differential between the estimated initial value and the issue price of the Securities as of the trade date - We may determine the economic terms of the Securities, as well as

hedge our obligations, at least in part, prior to pricing the Securities on the trade date. In addition, there may be ongoing costs to us to maintain and/or adjust any hedges and such hedges are often imperfect. Therefore, our actual profits (or potentially, losses) in issuing the Securities cannot be determined as of the trade date and any such differential between the estimated initial value and the issue price of the Securities as of the trade date does not reflect our actual profits. Ultimately, our actual profits will be known only at the maturity of the Securities.

• **Limited or no secondary market and secondary market price considerations.**

• **There may be little or no secondary market for the Securities** - The Securities will not be listed or displayed on any securities exchange or any electronic communications network. There can be no assurance that a secondary market for the Securities will develop. UBS Securities LLC and its affiliates may make a market in each offering of the Securities, although they are not required to do so and may stop making a market at any time. If you are able to sell your Securities prior to maturity, you may have to sell them at a substantial loss. The estimated initial value of the Securities does not represent a minimum or maximum price at which we or any of our affiliates would be willing to purchase your Securities in any secondary market at any time.

• **The price at which UBS Securities LLC and its affiliates may offer to buy the Securities in the secondary market (if any) may be greater than UBS' valuation of the Securities at that time, greater than any other secondary market prices provided by unaffiliated dealers (if any) and, depending on your broker, greater than the valuation provided on your customer account statements** - For a limited period of time following the issuance of the Securities, UBS Securities LLC or its affiliates may offer to buy or sell such Securities at a price that exceeds (i) our valuation of the Securities at that time based on our internal pricing models, (ii) any secondary market prices provided by unaffiliated dealers (if any) and (iii) depending on your broker, the valuation provided on customer account statements. The price that UBS Securities LLC may initially offer to buy such Securities following issuance will exceed the valuations indicated by our internal pricing models due to the inclusion for a limited period of time of the aggregate value of the underwriting discount, hedging costs, issuance costs and theoretical projected trading profit. The portion of such amounts included in our price will decline to zero on a straight line basis over a period ending no later than the date specified under

• “Supplemental Plan of Distribution (Conflicts of Interest); Secondary Markets (if any).” Thereafter, if UBS Securities LLC or an affiliate makes secondary markets for the Securities, it will do so at prices that reflect our estimated value determined by reference to our internal pricing models at that time. The temporary positive differential relative to our internal pricing models arises from requests from and arrangements made by UBS Securities LLC with the selling agents of structured debt securities such as the Securities. As described above, UBS Securities LLC and its affiliates are not required to make a market for the Securities and may stop making a market at any time. The price at which UBS Securities LLC or an affiliate may make secondary markets at any time (if at all) will also reflect its then current bid-ask spread for similar sized trades of structured debt securities. UBS Financial Services Inc. and UBS Securities LLC reflect this temporary positive differential on their customer statements. Investors should inquire as to the valuation provided on customer account statements provided by unaffiliated dealers.

Price of Securities prior to maturity - The market price of the Securities will be influenced by many unpredictable and interrelated factors, including the price of the underlying asset; the volatility of the underlying asset; the dividend rate paid on the underlying asset; the time remaining to the maturity of the Securities; interest rates in the markets; geopolitical conditions and economic, financial, political, force majeure and regulatory or judicial events; the creditworthiness of UBS and the then current bid-ask spread for the Securities.

Impact of fees and the use of internal funding rates rather than secondary market credit spreads on secondary market prices - All other things being equal, the use of the internal funding rates described above under “- Fair value considerations” as well as the inclusion in the issue price of the underwriting discount, hedging costs, issuance costs and any projected profits are, subject to the temporary mitigating effect of UBS Securities LLC’s and its affiliates’ market making premium, expected to reduce the price at which you may be able to sell the Securities in any secondary market.

Owning the Securities is not the same as owning the underlying asset - The return on your Securities may not reflect the return you would realize if you actually owned the underlying asset. For instance, you will not receive or be entitled to receive any dividend payments or other distributions on the underlying asset over the term of your Securities. Furthermore, the underlying asset may appreciate substantially during the term of your Securities and you will not participate in such appreciation.

No assurance that the investment view implicit in the Securities will be successful - It is impossible to predict whether and the extent to which the price of the underlying asset will rise or fall. The price of the underlying asset will be influenced by complex and interrelated political, economic, financial and other factors that affect the underlying asset issuer. You should be willing to accept the risks of owning equities in general and the underlying asset in particular, and the risk of losing a significant portion or all of your initial investment.

There is no affiliation between the underlying asset issuer, or for Securities linked to exchange traded funds, the issuers of the constituent stocks comprising the underlying asset (the "underlying asset constituent stock issuers"), and UBS, and UBS is not responsible for any disclosure by such issuer(s) - We and our affiliates may currently, or from time to time in the future engage in business with the underlying asset issuer or, if applicable, any underlying asset constituent stock issuers. However, we are not affiliated with the underlying asset issuer or any underlying asset constituent stock issuers and are not responsible for such issuer’s public disclosure of information, whether contained in SEC filings or otherwise. You, as an investor in the Securities, should make your own investigation into the underlying asset issuer or, if applicable, each underlying asset constituent stock issuer. Neither the underlying asset issuer nor any underlying asset constituent stock issuer is involved in the Securities offered hereby in any way and has no obligation of any sort with respect to your Securities. Such issuer(s) have no obligation to take your interests into consideration for any reason, including when taking any corporate actions that might affect the value of, and any amounts payable on, your Securities.

The calculation agent can make adjustments that affect the payment to you at maturity- For certain corporate events affecting the underlying asset, the calculation agent may make adjustments to the initial price, the coupon barrier, the trigger price and/or the final price of the underlying asset. However, the calculation agent will not make an adjustment in response to all events that could affect the underlying asset. If an event occurs that does not require the calculation agent to make an adjustment, the value of the Securities may be materially and adversely affected. In addition, all determinations and calculations concerning any such adjustments will be made by the calculation agent. You should be aware that the calculation agent may make any such adjustment, determination or calculation in a manner that differs from that discussed in the accompanying product supplement as necessary to achieve an equitable result. In the case of common stock or American depositary receipts, following certain corporate events relating to the issuer of the underlying asset where the issuer is not the surviving entity, the amount of cash you receive at maturity may be based on the common stock or American depositary receipts of a successor to the underlying asset issuer in combination with any cash or any other assets distributed to holders of the underlying

asset in such corporate event. Additionally, if the issuer of the underlying asset becomes subject to (i) a reorganization event whereby the underlying asset is exchanged solely for cash, (ii) a merger or consolidation with UBS or any of its affiliates or (iii) an underlying asset is delisted or otherwise suspended from trading, the amount you receive at maturity may be based on the common stock or American depositary receipts issued by another company. In the case of an exchange traded fund, following a suspension from trading or if an exchange traded fund is discontinued, the amount you receive at maturity may be based on a share of another exchange traded fund. The occurrence of these corporate events and the consequent adjustments may materially and adversely affect the value of the Securities. For more information, see the sections "General Terms of the Securities -- Antidilution Adjustments for Securities Linked to an Underlying Asset or Equity Basket Asset" and " --Reorganization Events for Securities Linked to an Underlying Asset or Equity Basket Asset" in the accompanying product supplement. Regardless of the occurrence of one or more dilution or reorganization events, you should note that at maturity UBS will pay you an amount in cash equal to your principal amount, unless the final price of the underlying asset is below the trigger price (as such trigger price may be adjusted by the calculation agent upon occurrence of one or more such events). Regardless of any of the events discussed above, any payment on the Securities is subject to the creditworthiness of UBS.

The value of the underlying equity may not completely track the value of the securities in which such exchange traded fund invests — The underlying equity may be an exchange traded fund, and although the trading characteristics and valuations of such underlying equity will usually mirror the characteristics and valuations of the securities in which such exchange traded fund invests, its value may not completely track the value of such securities. The value of the underlying equity will reflect transaction costs and fees that the securities in which that exchange traded fund invests do not have. In addition, although the underlying equity may be currently listed for trading on an exchange, there is no assurance that an active trading market will continue for such underlying equity or that there will be liquidity in the trading market.

Fluctuation of NAV — The net asset value (the "NAV") of an exchange traded fund may fluctuate with changes in the market value of such exchange traded fund's securities holdings. The market prices of the underlying equity may fluctuate in accordance with changes in NAV and supply and demand on the applicable stock exchanges. In addition, the market price of the underlying equity may differ from its NAV per share; the underlying equity may trade at, above or below its NAV per share.

Failure of the underlying equity to track the level of the underlying index — The underlying equity may be an exchange traded fund. Such underlying equity may be designed and intended to track the level of a specific index (an "underlying index"), but various factors, including fees and other transaction costs, may prevent the underlying equity from correlating exactly with changes in the level of such underlying index. Accordingly, the performance of the underlying equity may not be equal to the performance of its underlying index.

Potential UBS impact on the market price of the underlying asset - Trading or transactions by UBS or its affiliates in the underlying asset and/or over-the-counter options, futures or other instruments with returns linked to the performance of the underlying asset may adversely affect the market price of the underlying asset and, therefore, the market value of, and any amounts payable on, your Securities.

Potential conflict of interest - UBS and its affiliates may engage in business with the issuer of the underlying asset, which may present a conflict between the obligations of UBS and you, as a holder of the Securities. There are also potential conflicts of interest between you and the calculation agent, which will be an affiliate of UBS. The calculation agent will determine whether the final price is below the trigger price and accordingly the payment at maturity on your Securities. The calculation agent may also postpone the determination of the final price and the maturity date if a market disruption event occurs and is continuing on the final valuation date and may make adjustments to the initial price, the trigger price, the coupon barrier, the final price and/or the underlying asset itself for certain corporate events affecting the underlying asset. For more information, see the sections "General Terms of the Securities -- Antidilution Adjustments for Securities Linked to an Underlying Asset or Equity Basket Asset" and " --Reorganization Events for Securities Linked to an Underlying Asset or Equity Basket Asset" in the accompanying product supplement. As UBS determines the economic terms of the Securities, including the contingent coupon rate, trigger price and coupon barrier, and such terms include the underwriting discount, hedging costs, issuance costs and projected profits, the Securities represent a package of economic terms. There are other potential conflicts of interest insofar as an investor could potentially get better economic terms if that investor

entered into exchange-traded and/or OTC derivatives or other instruments with third parties, assuming that such instruments were available and the investor had the ability to assemble and enter into such instruments.

Potentially inconsistent research, opinions or recommendations by UBS - UBS and its affiliates publish research from time to time on financial markets and other matters that may influence the value of the Securities, or express opinions or provide recommendations that are inconsistent with purchasing or holding the Securities. Any research, opinions or recommendations expressed by UBS or its affiliates may not be consistent with each other and may be modified from time to time without notice. Investors should make their own independent investigation of the merits of investing in the Securities and the underlying asset to which the Securities are linked.

The Securities are not bank deposits - An investment in the Securities carries risks which are very different from the risk profile of a bank deposit placed with UBS or its affiliates. The Securities have different yield and/or return, liquidity and risk profiles and would not benefit from any protection provided to deposits.

If UBS experiences financial difficulties, FINMA has the power to open restructuring or liquidation proceedings in respect of, and/or impose protective measures in relation to, UBS, which proceedings or measures may have a material adverse effect on the terms and market value of the Securities and/or the ability of UBS to make payments thereunder - The Swiss Financial Market Supervisory Authority (“FINMA”) has broad statutory powers to take measures and actions in relation to UBS if (i) it concludes that there is justified concern that UBS is over-indebted or has serious liquidity problems or (ii) UBS fails to fulfil the applicable capital adequacy requirements (whether on a standalone or consolidated basis) after expiry of a deadline set by FINMA. If one of these pre-requisites is met, FINMA is authorized to open restructuring proceedings or liquidation (bankruptcy) proceedings in respect of, and/or impose protective measures in relation to, UBS. The Swiss Banking Act grants significant discretion to FINMA in connection with the aforementioned proceedings and measures. In particular, a broad variety of protective measures may be imposed by FINMA, including a bank moratorium or a maturity postponement, which measures may be ordered by FINMA either on a stand-alone basis or in connection with restructuring or liquidation proceedings. The resolution regime of the Swiss Banking Act is further detailed in the FINMA Banking Insolvency Ordinance (“BIO-FINMA”). In a restructuring proceeding, FINMA, as resolution authority, is competent to approve the resolution plan. The resolution plan may, among other things, provide for (a) the transfer of all or a portion of UBS’s assets, debts, other liabilities and contracts (which may or may not include the contractual relationship between UBS and the holders of Securities) to another entity, (b) a stay (for a maximum of two business days) on the termination of contracts to which UBS is a party, and/or the exercise of (w) rights to terminate, (x) netting rights, (y) rights to enforce or dispose of collateral or (z) rights to transfer claims, liabilities or collateral under contracts to which UBS is a party, (c) the conversion of UBS’s debt and/or other obligations, including its obligations under the Securities, into equity (a “debt-to-equity” swap), and/or (d) the partial or full write-off of obligations owed by UBS (a “write-off”), including its obligations under the Securities. The BIO-FINMA provides that a debt-to-equity swap and/or a write-off of debt and other obligations (including the Securities) may only take place after (i) all debt instruments issued by UBS qualifying as additional tier 1 capital or tier 2 capital have been converted into equity or written-off, as applicable, and (ii) the existing equity of UBS has been fully cancelled. While the BIO-FINMA does not expressly address the order in which a write-off of debt instruments other than debt instruments qualifying as additional tier 1 capital or tier 2 capital should occur, it states that debt-to-equity swaps should occur in the following order: first, all subordinated claims not qualifying as regulatory capital; second, all other claims not excluded by law from a debt-to-equity swap (other than deposits); and third, deposits (in excess of the amount privileged by law). However, given the broad discretion granted to FINMA as the resolution authority, any restructuring plan in respect of UBS could provide that the claims under or in connection with the Securities will be partially or fully converted into equity or written-off, while preserving other obligations of UBS that rank pari passu with, or even junior to, UBS’s obligations under the Securities. Consequently, holders of Securities may lose all or some of their investment in the Securities. In the case of restructuring proceedings with respect to a systemically important Swiss bank (such as UBS), the creditors whose claims are affected by the restructuring plan will not have a right to vote on, reject, or seek the suspension of the restructuring plan. In addition, if a restructuring plan has been approved by FINMA, the rights of a creditor to seek judicial review of the restructuring plan (e.g., on the grounds that the plan would unduly prejudice the rights of holders of Securities or otherwise be in violation of the Swiss Banking Act) are very limited. In particular, a court may not suspend the implementation of the restructuring plan. Furthermore, even if a creditor successfully challenges the restructuring

plan, the court can only require the relevant creditor to be compensated ex post and there is currently no guidance as to on what basis such compensation would be calculated or how it would be funded.

Dealer incentives - UBS and its affiliates act in various capacities with respect to the Securities. We and our affiliates may act as a principal, agent or dealer in connection with the sale of the Securities. Such affiliates, including the sales representatives, will derive compensation from the distribution of the Securities and such compensation may serve as an incentive to sell these Securities instead of other investments. We will pay total underwriting compensation of 1.50% per Security to any of our affiliates acting as agents or dealers in connection with the distribution of the Securities. Given that UBS Securities LLC and its affiliates temporarily maintain a market making premium, it may have the effect of discouraging UBS Securities LLC and its affiliates from recommending sale of your Securities in the secondary market.

Uncertain tax treatment - Significant aspects of the tax treatment of the Securities are uncertain. You should read carefully the sections entitled "What are the Tax Consequences of the Securities" herein and in the prospectus supplement and "Material U.S. Federal Income Tax Consequences" in the accompanying product supplement, and consult your tax advisor about your tax situation.

The Securities are subject to risks associated Mortgage REITs - Mortgage REITs, which invest the majority of their assets in real estate mortgages, receive principal and interest payments from the owners of the mortgage properties and derive their income primarily from interest payments. Accordingly, Mortgage REITs are subject to the credit risk of the borrowers, which refers to the possibility that the borrower will be unable and/or unwilling to make timely interest payments and/or repay the principal on the loan to the Mortgage REIT when due. In the event of a default by a borrower, the Mortgage REIT may experience delays in enforcing its rights as a mortgagee and may incur substantial costs associated with protecting its investments. Mortgage REITs are subject to heavy cash flow dependency and, as a result, are particularly reliant on the proper functioning of the capital markets. Further, Mortgage REITs are dependent upon specialized management skills and their investments may not be diversified. Mortgage REITs are also subject to risks related to general and local economic conditions and the real estate market specifically, availability of mortgage funds, changes in interest rates, changes in property values, and borrower prepayment on underlying mortgage loans. In addition, a Mortgage REIT could fail to qualify for favorable tax or regulatory treatment.

The Securities are subject to risks associated with the financial sector - The Financial Select Sector SPDR® Fund (the "XLF Fund") seeks to track the performance of the Financial Select Sector Index, which is comprised of the stocks of companies representing the financial sector of the S&P 500® Index. The XLF Fund may be subject to increased price volatility as its holdings are concentrated in a single industry and may be more susceptible to economic, market, political or regulatory occurrences affecting that industry. Financial services companies are subject to extensive governmental regulation which may limit both the amounts and types of loans and other financial commitments they can make, the interest rates and fees they can charge, the scope of their activities, the prices they can charge and the amount of capital they must maintain. Profitability is largely dependent on the availability and cost of capital funds and can fluctuate significantly when interest rates change or due to increased competition. In addition, deterioration of the credit markets generally may cause an adverse impact in a broad range of markets, including U.S. and international credit and interbank money markets generally, thereby affecting a wide range of financial institutions and markets. Certain events in the financial sector may cause an unusually high degree of volatility in the financial markets, both domestic and foreign, and cause certain financial services companies to incur large losses. Securities of financial services companies may experience a dramatic decline in value when such companies experience substantial declines in the valuations of their assets, take action to raise capital (such as the issuance of debt or equity securities), or cease operations. Credit losses resulting from financial difficulties of borrowers and financial losses associated with investment activities can negatively impact the sector. Insurance companies may be subject to severe price competition. Adverse economic, business or political developments affecting real estate could have a major effect on the value of real estate securities (which include real estate investment trusts). Declining real estate values could adversely affect financial institutions engaged in mortgage finance or other lending or investing activities directly or indirectly connected to the value of real estate.

The XLF Fund utilizes a passive indexing investment approach - The XLF Fund is not managed according to traditional methods of "active" investment management, which involve the buying and selling of securities based on economic, financial and market analysis and investment judgment. Instead, the XLF Fund, utilizing a "passive" or

indexing investment approach, attempts to approximate the investment performance of the Financial Select Sector Index by investing in a portfolio of stocks that generally replicate such index. Therefore, unless a specific stock is removed from that index, the XLF Fund generally would not sell a stock because the stock's issuer was in financial trouble. In addition, the XLF Fund is subject to the risk that the investment strategy of the XLF Fund's investment adviser may not produce the intended results.

Information about the Underlying Asset

All disclosures regarding the underlying asset are derived from publicly available information. UBS has not conducted any independent review or due diligence of any publicly available information with respect to the underlying asset. **You should make your own investigation into the underlying asset.**

The underlying asset will be registered under the Securities Act of 1933, the Securities Exchange Act of 1934 (as amended, the "Exchange Act") and/or the Investment Company Act of 1940, each as amended. Companies with securities registered with the SEC are required to file financial and other information specified by the SEC periodically. Information filed by the underlying asset issuer with the SEC can be reviewed electronically through a website maintained by the SEC. The address of the SEC's website is <http://www.sec.gov>. Information filed with the SEC by the underlying asset issuer can be located by reference to its SEC file number provided below. In addition, information filed with the SEC can be inspected and copied at the Public Reference Section of the SEC, 100 F Street, N.E., Room 1580, Washington, D.C. 20549. Copies of this material can also be obtained from the Public Reference Section, at prescribed rates.

The Financial Select Sector SPDR® Fund

"We have derived all information contained herein regarding The Financial Select Sector SPDR® Fund (the "XLF Fund") from publicly available information. Such information reflects the policies of, and is subject to change by, SSgA Funds Management, Inc., the investment adviser of the XLF Fund. UBS has not undertaken an independent review or due diligence of any publicly available information regarding the XLF Fund.

The XLF Fund is one of the separate investment portfolios (each, a "Select Sector SPDR Fund") that constitute The Select Sector SPDR® Trust (the "Trust"). Each Select Sector SPDR Fund is an "index fund" that invests in a particular sector or group of industries represented by a specified Select Sector Index. The companies included in each Select Sector Index are selected on the basis of general industry classification from a universe of companies defined by the S&P 500® Index ("S&P 500"). The Select Sector Indices upon which the Select Sector SPDR Funds are based together comprise all of the companies in the S&P 500. The XLF Fund seeks to provide investment results that, before expenses, correspond generally to the price and yield performance of publicly traded equity securities of companies in the Financial Select Sector Index (the "target index").

In seeking to track the performance of the target index, the XLF Fund employs a replication strategy, which means that the XLF Fund typically invests in substantially all of the securities represented in the target index in approximately the same proportions as the target index. Under normal market conditions, the XLF Fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the target index.

The target index includes companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts ("Mortgage REITs"); consumer finance; thrifts and mortgage finance. The target index is one of the Select Sector Indices developed and maintained in accordance with the following criteria: (1) each of the component securities in a Select Sector Index is a constituent company of the S&P 500 and (2) each Select Sector Index is calculated by Standard & Poor's using a modified "market capitalization"

methodology, which means that modifications may be made to the market capitalization weights of single stock concentrations in order to conform to the requirements of the Internal Revenue Code of 1986, as amended.

As of March 31, 2017, ordinary operating expenses of the XLF Fund are expected to accrue at an annual rate of 0.14% of the XLF Fund's average daily net asset value. Expenses of the XLF Fund reduce the net value of the assets held by the XLF Fund and, therefore, reduce the value of each share of the XLF Fund. As of March 31, 2017, the XLF Fund's five largest company holdings include: Berkshire Hathaway Inc. Class B (10.85%), JPMorgan Chase & Co. (10.76%), Wells Fargo & Company (8.60%), Bank of America Corporation (8.11%) and Citigroup Inc. (5.68%).

As of the close of business on September 16, 2016 (the "Rebalance Date") the target index was reconstituted by eliminating the stocks of real estate management and development companies and real estate investment trusts ("REITs") (other than mortgage REITs) ("Real Estate Stocks") and to effectuate a corresponding change to its portfolio, the XLF Fund transferred Real Estate Stocks to The Real Estate Select Sector SPDR Fund (the "XLRE Fund") in exchange for shares of the XLRE Fund and, made an in-kind distribution of the XLRE Fund shares to shareholders of the XLF Fund such that, following the distribution, the XLF Fund continued to hold stocks included in the reconstituted target index in accordance with its principal investment strategy.

In making your investment decision you should review the prospectus related to the XLF Fund, dated January 31, 2017 (as amended May 1, 2017), filed by The Select Sector SPDR® Trust (the "XLF Fund Prospectus") available at:

January 31, 2017

sec.gov/Archives/edgar/data/1064641/000119312517021995/d281803d485bpos.htm

May 1, 2017

sec.gov/Archives/edgar/data/1064641/000119312517152121/d387698d497.htm

In addition, the XLF Fund Prospectus is available on the XLF Fund's website as indicated below. In making your investment decision you should pay particular attention to the sections of the XLF Fund Prospectus entitled "Principal Risks of Investing in the Fund" and "Additional Risk Information." UBS has not undertaken an independent review or due diligence of any publicly available information regarding the XLF Fund Prospectus, and such information is not incorporated by reference in, and should not be considered part of, this document or any accompanying prospectus.

The XLF Fund's website is spdrs.com/product/fund.seam?ticker=XLF. Shares of the XLF Fund are listed on the NYSE Arca under ticker symbol "XLF."

Information filed by The Select Sector SPDR® Trust with the SEC can be found by reference to its SEC file numbers: 333-57791 and 811-08837.

"

Information from outside sources is not incorporated by reference in, and should not be considered part of, this preliminary terms supplement or any accompanying prospectus. UBS has not conducted any independent review or due diligence of any publicly available information with respect to the underlying asset.

Historical Information

The following table sets forth the quarterly high and low closing prices for XLF Fund's shares, based on daily closing prices on the primary exchange for XLF Fund. We obtained the closing prices below from Bloomberg Professional service ("Bloomberg"), without independent verification. UBS has not undertaken an independent review or due diligence of any publicly available information obtained from Bloomberg. XLF Fund's closing price on December 26, 2018 was \$23.32. The actual initial price will be the closing price of XLF Fund's shares on the trade date. **Past performance of the underlying asset is not indicative of the future performance of the underlying asset.**

Quarter Begin	Quarter End	Quarterly High	Quarterly Low	Quarterly Close
01/02/2014	03/31/2014	\$18.25	\$16.67	\$18.14
04/01/2014	06/30/2014	\$18.60	\$17.28	\$18.46
07/01/2014	09/30/2014	\$19.33	\$17.99	\$18.81
10/01/2014	12/31/2014	\$20.33	\$17.90	\$20.08
01/02/2015	03/31/2015	\$20.08	\$18.68	\$19.58
04/01/2015	06/30/2015	\$20.52	\$19.56	\$19.80
07/01/2015	09/30/2015	\$20.77	\$18.09	\$18.40
10/01/2015	15/01/2010			Director/PDMR Shareholding
15/01/2010	4:30 PM	Director/PDMR Shareholding		
15/01/2010	4:30 PM	Director/PDMR Shareholding		
14/01/2010	5:00 PM	Director/PDMR Shareholding		
14/01/2010	4:53 PM	Director/PDMR Shareholding		
14/01/2010	4:44 PM	Director/PDMR Shareholding		
13/01/2010	4:30 PM	Director/PDMR Shareholding		
13/01/2010	4:30 PM	Director/PDMR Shareholding		
13/01/2010	2:45 PM	The Saudi British Bank 2009 Results - Highlights		
13/01/2010	7:00 AM	Third Interim Dividend 2009 - Scrip Alternative		
06/01/2010	4:30 PM	Overseas Regulatory Announcement		
05/01/2010	4:20 PM	Director/PDMR Shareholding		
04/01/2010	12:00 PM	Dividend Exchange Rates		
31/12/2009	12:00 PM	Director/PDMR Shareholding		
31/12/2009	12:00 PM	Total Voting Rights		

Edgar Filing: UBS AG - Form 424B2

30/12/2009	4:30 PM	Director/PDMR Shareholding HSBC agrees sale and leaseback of Paris properties
21/12/2009	2:00 PM	HSBC Sells Insurance Broking
18/12/2009	12:00 PM	Hang Seng Bank - 2010 Part-Year Caps
18/12/2009	10:00 AM	Documents available at UKLA
01/12/2009	10:41 AM	Scrip Dividend Circular
01/12/2009	10:39 AM	Sale of HSBC Actuaries and Consultants Ltd
01/12/2009	8:20 AM	Director/PDMR Shareholding
30/11/2009	4:30 PM	Director/PDMR Shareholding
30/11/2009	4:30 PM	Director/PDMR Shareholding
30/11/2009	4:20 PM	Total Voting Rights 3rd Interim Dividend for 2009 - Scrip Alternative
25/11/2009	10:30 AM	Bank Ekonomi Q3 2009 Results
20/11/2009	8:30 AM	Statement
18/11/2009	12:30 PM	HSBC Agrees Sale of 8 Canada Square
13/11/2009	5:10 PM	HSBC Bank Malta Interim Directors' Statement
13/11/2009	11:00 AM	HSBC Bank Malaysia Berhad Results to 30 Sept 09
13/11/2009	8:30 AM	HSBC Trinkaus & Burkhardt 3rd Quarter Results
12/11/2009	10:00 AM	HSBC Bank Canada Third Quarter 2009 Results
11/11/2009	9:30 AM	HSBC USA Inc Q3 2009 - Form 10-Q
10/11/2009	8:15 AM	HSBC Finance Corporation Q3 2009 - Form 10-Q
10/11/2009	8:15 AM	Interim Management Statement
02/11/2009	8:36 AM	Hang Seng Bk 3rd interim dividend
02/11/2009	8:20 AM	Third interim dividend
30/10/2009	4:30 PM	Director/PDMR Shareholding
30/10/2009	4:30 PM	Total Voting Rights Grupo Financiero HSBC 3Q 2009 Financial Results
30/10/2009	3:00 PM	InvestDirect results for 2Q to 30SEP09
29/10/2009	1:32 PM	Director/PDMR Shareholding
28/10/2009	4:30 PM	HSBC and BoCom plan JV for Chinese credit card ops
28/10/2009	9:00 AM	HSBC France sells custody and fund admin ops
26/10/2009	10:00 AM	HSBC to increase stake in Bao Viet
22/10/2009	10:50 AM	Board Meeting
14/10/2009	10:00 AM	The Saudi British Bank Third Quarter 2009 Results
13/10/2009	8:45 AM	Director/PDMR Shareholding
12/10/2009	4:51 PM	Director/PDMR Shareholding
12/10/2009	4:49 PM	Director/PDMR Shareholding
12/10/2009	4:47 PM	Director/PDMR Shareholding
12/10/2009	4:45 PM	Director/PDMR Shareholding
12/10/2009	4:42 PM	Director/PDMR Shareholding
09/10/2009	4:35 PM	Director/PDMR Shareholding

Edgar Filing: UBS AG - Form 424B2

09/10/2009	4:35 PM	Director/PDMR Shareholding
09/10/2009	4:30 PM	Director/PDMR Shareholding
09/10/2009	4:30 PM	Director/PDMR Shareholding
09/10/2009	4:30 PM	Director/PDMR Shareholding
08/10/2009	4:40 PM	Director/PDMR Shareholding
08/10/2009	4:39 PM	Director/PDMR Shareholding
08/10/2009	4:37 PM	Director/PDMR Shareholding
07/10/2009	4:57 PM	Director/PDMR Shareholding
07/10/2009	4:52 PM	Director/PDMR Shareholding
		Second Interim Dividend 2009 - Scrip
07/10/2009	7:00 AM	Alternative
		HSBC - SALE AND LEASEBACK OF 452
		FIFTH AVENUE, NY
05/10/2009	7:00 AM	
30/09/2009	5:00 PM	Total Voting Rights
30/09/2009	5:00 PM	Director/PDMR Shareholding
29/09/2009	4:30 PM	Director/PDMR Shareholding
28/09/2009	1:00 PM	Dividend exchange rates
25/09/2009	9:15 AM	HSBC strengthens emerging markets focus
23/09/2009	5:00 PM	Overseas Regulatory Announcement
18/09/2009	12:00 PM	Director/PDMR Shareholding
16/09/2009	3:10 PM	Director/PDMR Shareholding
08/09/2009	12:30 PM	Director/PDMR Shareholding
04/09/2009	10:00 AM	HSBC Poland - sale of portfolios
01/09/2009	5:37 PM	Scrip Dividend Circular
01/09/2009	4:30 PM	Documents available at UKLA
01/09/2009	7:09 AM	Bank Ekonomi 1H2009 results
28/08/2009	5:30 PM	Total Voting Rights
28/08/2009	5:30 PM	Director/PDMR Shareholding
27/08/2009	5:00 PM	Director/PDMR Shareholding
26/08/2009	10:00 AM	2009 2nd int div - scrip alternative
25/08/2009	4:30 PM	Director/PDMR Shareholding
19/08/2009	4:30 PM	Director/PDMR Shareholding
18/08/2009	3:30 PM	Redemption of subordinated notes
14/08/2009	4:50 PM	Interim Report - 21 of 21
14/08/2009	4:49 PM	Interim Report - 20 of 21
14/08/2009	4:48 PM	Interim Report - 19 of 21
14/08/2009	4:47 PM	Interim Report - 18 of 21
14/08/2009	4:46 PM	Interim Report - 17 of 21
14/08/2009	4:45 PM	Interim Report - 16 of 21
14/08/2009	4:44 PM	Interim Report - 15 of 21
14/08/2009	4:43 PM	Interim Report - 14 of 21
14/08/2009	4:42 PM	Interim Report - 13 of 21
14/08/2009	4:41 PM	Interim Report - 12 of 21
14/08/2009	4:40 PM	Interim Report - 11 of 21
14/08/2009	4:39 PM	Interim Report - 10 of 21
14/08/2009	4:38 PM	Interim Report - 9 of 21
14/08/2009	4:37 PM	Interim Report - 8 of 21
14/08/2009	4:36 PM	Interim Report - 7 of 21
14/08/2009	4:35 PM	Interim Report - 6 of 21
14/08/2009	4:34 PM	Interim Report - 5 of 21
14/08/2009	4:33 PM	Interim Report - 4 of 21

Edgar Filing: UBS AG - Form 424B2

14/08/2009	4:32 PM	Interim Report - 3 of 21
14/08/2009	4:31 PM	Interim Report - 2 of 21
14/08/2009	4:30 PM	Interim Report - 1 of 21
14/08/2009	4:30 PM	Interim Report 2009
13/08/2009	10:00 AM	HSBC Trinkaus 1H2009 results
12/08/2009	7:31 AM	Bank Ekonomi - completion of MTO
11/08/2009	4:35 PM	Director/PDMR Shareholding
07/08/2009	9:29 AM	Dividend on US\$ pref shares Series A
03/08/2009	5:03 PM	Interim Report
		Int. Results Presentation to Investors &
03/08/2009	9:49 AM	Analysts
03/08/2009	9:18 AM	Hang Seng Bank 1H 2009 Results
		HSBC Finance Corporation 1H 2009 Form
		10-Q
03/08/2009	9:15 AM	HSBC USA Inc 1H 2009 Form 10-Q
03/08/2009	9:15 AM	Hongkong and Shanghai Banking Corp 1H
		2009 Results
03/08/2009	9:15 AM	HSBC Holdings plc Interim Results 2009
31/07/2009	4:30 PM	Total Voting Rights
		Grupo Financiero HSBC - First Half 2009
31/07/2009	3:00 PM	Results
		HSBC Bank Malta plc - First Half 2009
31/07/2009	11:30 AM	Results
30/07/2009	4:30 PM	Director/PDMR Shareholding
		IL&FS Investsmart Results: Quarter to 30
		June 09
30/07/2009	2:30 PM	Director/PDMR Shareholding
27/07/2009	5:00 PM	HSBC Bank Canada Second Quarter 2009
		Results
24/07/2009	9:30 AM	Director/PDMR Shareholding
15/07/2009	5:15 PM	SABB First Half 2009 Results
15/07/2009	2:11 PM	Replacement
14/07/2009	5:34 PM	Board Meeting
13/07/2009	4:30 PM	Director/PDMR Shareholding
13/07/2009	4:30 PM	Director/PDMR Shareholding
13/07/2009	4:30 PM	Director/PDMR Shareholding
13/07/2009	4:30 PM	Director/PDMR Shareholding
10/07/2009	4:30 PM	Director/PDMR Shareholding
10/07/2009	4:30 PM	Director/PDMR Shareholding
10/07/2009	4:30 PM	Director/PDMR Shareholding
09/07/2009	4:52 PM	Director/PDMR Shareholding
09/07/2009	4:50 PM	Director/PDMR Shareholding
08/07/2009	4:41 PM	Director/PDMR Shareholding
08/07/2009	4:30 PM	Director/PDMR Shareholding
08/07/2009	4:30 PM	Director/PDMR Shareholding
08/07/2009	7:00 AM	Scrip Dividend Alternative
03/07/2009	4:30 PM	Director/PDMR Shareholding
01/07/2009	5:00 PM	Blocklisting Interim Review
01/07/2009	4:30 PM	Director/PDMR Shareholding
30/06/2009	4:30 PM	Director/PDMR Shareholding
30/06/2009	4:30 PM	Total Voting Rights

Edgar Filing: UBS AG - Form 424B2

29/06/2009	12:45 PM	Dividend exchange rates
16/06/2009	11:17 AM	Offer to acq min interest in Investsmart Sale of 49% stake in HSBC Merchant Services
12/06/2009	12:46 PM	Services
10/06/2009	4:30 PM	Issuance of Subordinated Notes
09/06/2009	9:30 AM	Final approval - JV insurance co in China
03/06/2009	11:09 AM	Scrip Dividend Circular
03/06/2009	10:31 AM	Scrip Dividend Circular
01/06/2009	4:37 PM	Director/PDMR Shareholding
29/05/2009	4:30 PM	Total Voting Rights
28/05/2009	4:30 PM	Director/PDMR Shareholding First Interim Dividend 2009 - Scrip Alternative
28/05/2009	10:30 AM	Alternative
26/05/2009	7:00 AM	HSBC Bank Malaysia Berhad 1Q
22/05/2009	5:30 PM	HSBC USA Inc - Form 8-K
22/05/2009	4:42 PM	Result of AGM
22/05/2009	11:11 AM	AGM Statements
22/05/2009	8:00 AM	Acquisition of 88.89% of Bank Ekonomi
21/05/2009	6:10 PM	Director/PDMR Shareholding Director/PDMR Shareholding - Replacement
21/05/2009	6:10 PM	Replacement
20/05/2009	4:30 PM	Director/PDMR Shareholding
15/05/2009	11:30 AM	HSBC Malta Int Directors' Stmt HSBC Trinkaus & Burkhardt AG Q1 2009 Results
14/05/2009	10:00 AM	Results
13/05/2009	4:30 PM	Director/PDMR Shareholding - Replacement
11/05/2009	6:30 PM	Director/PDMR Shareholding
11/05/2009	5:31 PM	Director/PDMR Shareholding
11/05/2009	5:15 PM	Director/PDMR Shareholding
11/05/2009	5:15 PM	Director/PDMR Shareholding
11/05/2009	5:15 PM	Director/PDMR Shareholding
11/05/2009	5:15 PM	Director/PDMR Shareholding
11/05/2009	5:15 PM	Director/PDMR Shareholding
11/05/2009	5:15 PM	Director/PDMR Shareholding
11/05/2009	5:08 PM	Director/PDMR Shareholding
11/05/2009	4:54 PM	Director/PDMR Shareholding
11/05/2009	4:52 PM	Director/PDMR Shareholding
11/05/2009	4:50 PM	Director/PDMR Shareholding
11/05/2009	4:30 PM	Director/PDMR Shareholding
11/05/2009	4:30 PM	Director/PDMR Shareholding Capital and Risk Management Pillar 3 Disclosures
11/05/2009	9:20 AM	Disclosures
11/05/2009	9:15 AM	HSBC USA Inc. Form 10-Q for the First Quarter 2009 HSBC Finance Corporation Form 10-Q for Q1 2009
11/05/2009	9:15 AM	Q1 2009
11/05/2009	9:15 AM	Interim Management Statement
08/05/2009	6:30 PM	Director/PDMR Shareholding
08/05/2009	5:00 PM	Director/PDMR Shareholding
08/05/2009	5:00 PM	Director/PDMR Shareholding
07/05/2009	6:22 PM	Scrip Dividend Alternative - Market Value

Edgar Filing: UBS AG - Form 424B2

07/05/2009	10:00 AM	Savings Related Share Option Grant
07/05/2009	9:30 AM	HSBC Bank Canada 1Q09
06/05/2009	4:45 PM	Director/PDMR Shareholding
06/05/2009	4:45 PM	Director/PDMR Shareholding
06/05/2009	4:45 PM	Director/PDMR Shareholding
06/05/2009	4:45 PM	Director/PDMR Shareholding
06/05/2009	4:45 PM	Director/PDMR Shareholding
06/05/2009	7:00 AM	Scrip Dividend Alternative
05/05/2009	10:04 AM	Hang Seng Bank 1st int div First Interim Dividend for 2009 on Ordinary Shares
05/05/2009	9:45 AM	Shares
30/04/2009	4:30 PM	Director/PDMR Shareholding
30/04/2009	4:30 PM	Total Voting Rights
30/04/2009	1:00 PM	Grupo Financiero HSBC Q1 2009
29/04/2009	1:30 PM	Investsmart FY2008/2009 results
28/04/2009	4:30 PM	Director/PDMR Shareholding
27/04/2009	4:31 PM	Director/PDMR Shareholding
27/04/2009	4:30 PM	Director/PDMR Shareholding
27/04/2009	12:45 PM	Fourth Interim Dividend Payment
24/04/2009	4:15 PM	Director/PDMR Shareholding HSBC and British Arab Commercial Bank Limited
21/04/2009	9:45 AM	Limited
21/04/2009	9:30 AM	Board Meeting
15/04/2009	9:30 AM	SABB Q1 2009 results
09/04/2009	6:09 PM	Director/PDMR Shareholding
09/04/2009	6:00 PM	Director/PDMR Shareholding
09/04/2009	6:00 PM	Director/PDMR Shareholding
09/04/2009	6:00 PM	Director/PDMR Shareholding
09/04/2009	6:00 PM	Director/PDMR Shareholding
09/04/2009	6:00 PM	Director/PDMR Shareholding
09/04/2009	6:00 PM	Director/PDMR Shareholding
09/04/2009	5:35 PM	Director/PDMR Shareholding
09/04/2009	5:35 PM	Director/PDMR Shareholding
09/04/2009	5:35 PM	Director/PDMR Shareholding
09/04/2009	5:35 PM	Director/PDMR Shareholding
09/04/2009	5:35 PM	Director/PDMR Shareholding
09/04/2009	5:35 PM	Director/PDMR Shareholding
09/04/2009	5:35 PM	Director/PDMR Shareholding
09/04/2009	5:35 PM	Director/PDMR Shareholding
09/04/2009	5:35 PM	Director/PDMR Shareholding
09/04/2009	5:35 PM	Director/PDMR Shareholding
09/04/2009	5:35 PM	Director/PDMR Shareholding
09/04/2009	5:35 PM	Director/PDMR Shareholding
09/04/2009	5:35 PM	Director/PDMR Shareholding
09/04/2009	5:35 PM	Director/PDMR Shareholding
09/04/2009	5:35 PM	Director/PDMR Shareholding
09/04/2009	4:30 PM	Overseas Regulatory Announcement
09/04/2009	4:30 PM	Overseas Regulatory Announcement
09/04/2009	4:30 PM	Overseas Regulatory Announcement
09/04/2009	4:20 PM	Director/PDMR Shareholding
09/04/2009	4:20 PM	Director/PDMR Shareholding
09/04/2009	4:20 PM	Director/PDMR Shareholding
09/04/2009	4:20 PM	Director/PDMR Shareholding

Edgar Filing: UBS AG - Form 424B2

09/04/2009	4:20 PM	Director/PDMR Shareholding
09/04/2009	4:20 PM	Director/PDMR Shareholding
09/04/2009	4:20 PM	Director/PDMR Shareholding
09/04/2009	4:15 PM	Director/PDMR Shareholding-Replacement
08/04/2009	6:00 PM	Director/PDMR Shareholding
08/04/2009	6:00 PM	Director/PDMR Shareholding
08/04/2009	6:00 PM	Director/PDMR Shareholding
08/04/2009	6:00 PM	Director/PDMR Shareholding
08/04/2009	6:00 PM	Director/PDMR Shareholding
08/04/2009	4:30 PM	Overseas Regulatory Announcement
08/04/2009	4:30 PM	Overseas Regulatory Announcement
08/04/2009	4:30 PM	Overseas Regulatory Announcement
06/04/2009	12:30 PM	Successful Completion of Rights Issue
06/04/2009	7:00 AM	Strong Support for HSBC Rights Issue
03/04/2009	4:30 PM	Overseas Regulatory Announcement
03/04/2009	4:30 PM	Overseas Regulatory Announcement
02/04/2009	4:30 PM	Overseas Regulatory Announcement
02/04/2009	4:30 PM	Overseas Regulatory Announcement
02/04/2009	10:00 AM	HSBC Trinkaus 2008 results
01/04/2009	4:27 PM	Director/PDMR Shareholding
31/03/2009	6:33 PM	Scrip Dividend Circular
31/03/2009	5:30 PM	Documents available at UKLA
31/03/2009	5:30 PM	AGM Notice
31/03/2009	5:04 PM	Annual Report and Accounts - 35 of 35
31/03/2009	5:03 PM	Annual Report and Accounts - 34 of 35
31/03/2009	5:02 PM	Annual Report and Accounts - 33 of 35
31/03/2009	5:01 PM	Annual Report and Accounts - 32 of 35
31/03/2009	5:00 PM	Annual Report and Accounts - 31 of 35
31/03/2009	4:59 PM	Annual Report and Accounts - 30 of 35
31/03/2009	4:58 PM	Annual Report and Accounts - 29 of 35
31/03/2009	4:57 PM	Annual Report and Accounts - 28 of 35
31/03/2009	4:56 PM	Annual Report and Accounts - 27 of 35
31/03/2009	4:55 PM	Annual Report and Accounts - 26 of 35
31/03/2009	4:54 PM	Annual Report and Accounts - 25 of 35
31/03/2009	4:53 PM	Annual Report and Accounts - 24 of 35
31/03/2009	4:52 PM	Annual Report and Accounts - 23 of 35
31/03/2009	4:51 PM	Annual Report and Accounts - 22 of 35
31/03/2009	4:50 PM	Annual Report and Accounts - 21 of 35
31/03/2009	4:49 PM	Annual Report and Accounts - 20 of 35
31/03/2009	4:48 PM	Annual Report and Accounts - 19 of 35
31/03/2009	4:47 PM	Annual Report and Accounts - 18 of 35
31/03/2009	4:46 PM	Annual Report and Accounts - 17 of 35
31/03/2009	4:45 PM	Annual Report and Accounts - 16 of 35
31/03/2009	4:44 PM	Annual Report and Accounts - 15 of 35
31/03/2009	4:43 PM	Annual Report and Accounts - 14 of 35
31/03/2009	4:42 PM	Annual Report and Accounts - 13 of 35
31/03/2009	4:41 PM	Annual Report and Accounts - 12 of 35
31/03/2009	4:40 PM	Annual Report and Accounts - 11 of 35
31/03/2009	4:39 PM	Annual Report and Accounts - 10 of 35
31/03/2009	4:38 PM	Annual Report and Accounts - 9 of 35

Edgar Filing: UBS AG - Form 424B2

31/03/2009	4:37 PM	Annual Report and Accounts - 8 of 35
31/03/2009	4:36 PM	Annual Report and Accounts - 7 of 35
31/03/2009	4:35 PM	Annual Report and Accounts - 6 of 35
31/03/2009	4:34 PM	Annual Report and Accounts - 5 of 35
31/03/2009	4:33 PM	Annual Report and Accounts - 4 of 35
31/03/2009	4:32 PM	Annual Report and Accounts - 3 of 35
31/03/2009	4:31 PM	Annual Report and Accounts - 2 of 35
31/03/2009	4:30 PM	Annual Report and Accounts 1 of 35
31/03/2009	4:29 PM	Total Voting Rights
30/03/2009	4.15 PM	Director/PDMR Shareholding

Documents filed with the United States Securities and Exchange Commission ('SEC')

During the 12 month period from 30

March 2009 (to include filings made to the London Stock Exchange after the announcement of the 2009 Annual Information Update on 30 March 2009) up to and including 29 March 2010, the Company also submitted the following filings to the SEC. The announcements can be viewed on and downloaded from the SEC's web-site at www.sec.gov

Filings	Description	Filing Date	File number	Film Number
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	29/03/2010	001-14930	10709384
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	24/03/2010	001-14930	10700517
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	17/03/2010	001-14930	10688263
20-F	Annual and transition report of foreign private issuers [Sections 13 or 15(d)]	15/03/2010	001-14930	10681154
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	11/03/2010	001-14930	10672972
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	11/03/2010	001-14930	10672295
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	09/03/2010	001-14930	10666144
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	03/03/2010	001-14930	10653328
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	03/03/2010	001-14930	10652950
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	03/03/2010	001-14930	10652941
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	03/03/2010	001-14930	10652921
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	03/03/2010	001-14930	10652846
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	03/03/2010	001-14930	10652832
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	03/03/2010	001-14930	10652677
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	03/03/2010	001-14930	10652655
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	03/03/2010	001-14930	10652650
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	03/03/2010	001-14930	10652646
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	03/03/2010	001-14930	10652599
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	03/03/2010	001-14930	10652529
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	03/03/2010	001-14930	10652523
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	03/03/2010	001-14930	10652512
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	03/03/2010	001-14930	10652501
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	03/03/2010	001-14930	10652490

Edgar Filing: UBS AG - Form 424B2

6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	02/03/2010	001-14930	10648734
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	02/03/2010	001-14930	10648687
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	02/03/2010	001-14930	10648511
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	02/03/2010	001-14930	10648450
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	02/03/2010	001-14930	10648355
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	02/03/2010	001-14930	10648282
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	01/03/2010	001-14930	10643005
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	26/02/2010	001-14930	10637263
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	26/02/2010	001-14930	10636844
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	26/02/2010	001-14930	10636090
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	22/02/2010	001-14930	10621098
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	19/02/2010	001-14930	10618161
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	18/02/2010	001-14930	10614973
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	18/02/2010	001-14930	10614966
	[Amend]Statement of acquisition of beneficial ownership			
SC 13G/A	by individuals	12/02/2010		
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	11/02/2010	001-14930	10590226
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	10/02/2010	001-14930	10586222
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	10/02/2010	001-14930	10586134
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	01/02/2010	001-14930	10561670
	Statement of acquisition of beneficial ownership by			
SC 13G	individuals	29/01/2010	005-50658	10559490
	[Amend]Report of foreign issuer [Rules 13a-16 and			
6-K/A	15d-16]	28/01/2010	001-14930	10552940
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	28/01/2010	001-14930	10552330
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	13/01/2010	001-14930	10524501
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	13/01/2010	001-14930	10523941
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	06/01/2010	001-14930	10510508
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	04/01/2010	001-14930	10500247
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	21/12/2009	001-14930	91251475
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	18/12/2009	001-14930	91248570
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	18/12/2009	001-14930	91248549
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	01/12/2009	001-14930	91213648
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	01/12/2009	001-14930	91213553
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	01/12/2009	001-14930	91213534
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	27/11/2009	001-14930	91209449
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	25/11/2009	001-14930	91206283
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	20/11/2009	001-14930	91197222
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	18/11/2009	001-14930	91192061
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	13/11/2009	001-14930	91180285
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	13/11/2009	001-14930	91179143
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	13/11/2009	001-14930	91179127
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	12/11/2009	001-14930	91173931
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	10/11/2009	001-14930	91170356
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	10/11/2009	001-14930	91170310
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	10/11/2009	001-14930	91170300
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	02/11/2009	001-14930	91149633
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]	02/11/2009	001-14930	91149631
6-K	Report of foreign issuer [Rules 13a-16 and 15d-16]			